94 Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
Bamias A, Van Der Heijden M, De Wit R, Fléchon A, Nishiyama H, Castellano D, Drakaki A, Matsubara N, Liepa A, Zimmermann A, Bell-Mcguinn K, Hamid O, Petrylak D, Powles T, Necchi A. 94 Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer. European Urology Open Science 2018, 17: e140-e141. DOI: 10.1016/s1569-9056(18)30946-1.Peer-Reviewed Original Research